Data from: Predictive value of apelin-12 in ST-elevation myocardial infarction patients with different renal function: a prospective observational study
Yang, Lingchang et al. (2017), Data from: Predictive value of apelin-12 in ST-elevation myocardial infarction patients with different renal function: a prospective observational study, Dryad, Dataset, https://doi.org/10.5061/dryad.pf56m
Objectives: To investigate the factors predicting the onset of major adverse cardiovascular events (MACEs) after primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI) patients. Background: apelin-12 has been regarded acting essential role in cardiovascular homeostasis. However, current knowledge of the optimal prognostic predictive value is limited. Methods: 464 STEMI patients (63.0±11.9 years, 355 men) who underwent successful pPCI were enrolled. Patients were followed-up for 2.5 years. Multivariate cox regression analyses and receiver operating characteristic curve analysis were performed to determine the factors predicting MACEs. Results: There were 118 patients (25.4%) who experienced MACEs in the follow-up period. Multivariate cox regression analysis demonstrated that low apelin-12 (HR=0.132, 95% CI=0.060-0.292, p＜0.001), low left ventricular ejection fraction (LVEF) (HR=0.965, 95% CI=0.941-0.991, p=0.007), low estimated glomerular filtration rate (eGFR) (HR=0.985, 95% CI=0.977-0.993, p＜0.001), Killip’s classification＞I (HR=0.610, 95% CI=0.408-0.912, p=0.016) and pathological Q-wave (HR=1.536, 95% CI=1.058-2.230, p=0.024) were independent predictors of 2.5 MACEs. Low apelin-12 could also predict worse in-hospital prognosis and showed advantage in predicting 2.5 year MACEs compared with Δapelin-12 (p=0.0115）and eGFR (p=0.0071) among patients with eGFR＞90 mL/min1.73m2. Further analysis prompt Δapelin-12＜20% was usually associated with MACEs in patients whose apelin-12 admission below 0.76 ng/ml (p=0.0075). Conclusions: STEMI patients receiving pPCI with lower apelin-12 are more likely to suffer MACEs in hospitalization and 2.5-year follow-up, especially for those with normal level of eGFR.